Cargando…
A Plant-Produced in vivo deglycosylated full-length Pfs48/45 as a Transmission-Blocking Vaccine Candidate against malaria
Pfs48/45 is a leading antigen candidate for a transmission blocking (TB) vaccine. However, efforts to produce affordable, safe and correctly folded full-length Pfs48/45 using different protein expression systems have not produced an antigen with satisfactory TB activity. Pfs48/45 has 16 cysteines in...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614448/ https://www.ncbi.nlm.nih.gov/pubmed/31285498 http://dx.doi.org/10.1038/s41598-019-46375-6 |
_version_ | 1783433186672377856 |
---|---|
author | Mamedov, Tarlan Cicek, Kader Miura, Kazutoyo Gulec, Burcu Akinci, Ersin Mammadova, Gunay Hasanova, Gulnara |
author_facet | Mamedov, Tarlan Cicek, Kader Miura, Kazutoyo Gulec, Burcu Akinci, Ersin Mammadova, Gunay Hasanova, Gulnara |
author_sort | Mamedov, Tarlan |
collection | PubMed |
description | Pfs48/45 is a leading antigen candidate for a transmission blocking (TB) vaccine. However, efforts to produce affordable, safe and correctly folded full-length Pfs48/45 using different protein expression systems have not produced an antigen with satisfactory TB activity. Pfs48/45 has 16 cysteines involved in disulfide bond formation, and the correct formation is critical for proper folding and induction of TB antibodies. Moreover, Pfs48⁄45 is not a glycoprotein in the native hosts, but contains potential glycosylation sites, which are aberrantly glycosylated during expression in eukaryotic systems. Here, we demonstrate for the first time that full length, Endo H in vivo enzymatic deglycosylated Pfs48/45 antigen is produced at a high level in plants and is structurally stable at elevated temperatures. Sera from mice immunized with this antigen showed strong inhibition in SMFA. Thus, Endo H in vivo enzymatic deglycosylated Pfs48/45 is a promising candidate for the development of an affordable TB vaccine, which may have the potential to save millions. |
format | Online Article Text |
id | pubmed-6614448 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-66144482019-07-17 A Plant-Produced in vivo deglycosylated full-length Pfs48/45 as a Transmission-Blocking Vaccine Candidate against malaria Mamedov, Tarlan Cicek, Kader Miura, Kazutoyo Gulec, Burcu Akinci, Ersin Mammadova, Gunay Hasanova, Gulnara Sci Rep Article Pfs48/45 is a leading antigen candidate for a transmission blocking (TB) vaccine. However, efforts to produce affordable, safe and correctly folded full-length Pfs48/45 using different protein expression systems have not produced an antigen with satisfactory TB activity. Pfs48/45 has 16 cysteines involved in disulfide bond formation, and the correct formation is critical for proper folding and induction of TB antibodies. Moreover, Pfs48⁄45 is not a glycoprotein in the native hosts, but contains potential glycosylation sites, which are aberrantly glycosylated during expression in eukaryotic systems. Here, we demonstrate for the first time that full length, Endo H in vivo enzymatic deglycosylated Pfs48/45 antigen is produced at a high level in plants and is structurally stable at elevated temperatures. Sera from mice immunized with this antigen showed strong inhibition in SMFA. Thus, Endo H in vivo enzymatic deglycosylated Pfs48/45 is a promising candidate for the development of an affordable TB vaccine, which may have the potential to save millions. Nature Publishing Group UK 2019-07-08 /pmc/articles/PMC6614448/ /pubmed/31285498 http://dx.doi.org/10.1038/s41598-019-46375-6 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Mamedov, Tarlan Cicek, Kader Miura, Kazutoyo Gulec, Burcu Akinci, Ersin Mammadova, Gunay Hasanova, Gulnara A Plant-Produced in vivo deglycosylated full-length Pfs48/45 as a Transmission-Blocking Vaccine Candidate against malaria |
title | A Plant-Produced in vivo deglycosylated full-length Pfs48/45 as a Transmission-Blocking Vaccine Candidate against malaria |
title_full | A Plant-Produced in vivo deglycosylated full-length Pfs48/45 as a Transmission-Blocking Vaccine Candidate against malaria |
title_fullStr | A Plant-Produced in vivo deglycosylated full-length Pfs48/45 as a Transmission-Blocking Vaccine Candidate against malaria |
title_full_unstemmed | A Plant-Produced in vivo deglycosylated full-length Pfs48/45 as a Transmission-Blocking Vaccine Candidate against malaria |
title_short | A Plant-Produced in vivo deglycosylated full-length Pfs48/45 as a Transmission-Blocking Vaccine Candidate against malaria |
title_sort | plant-produced in vivo deglycosylated full-length pfs48/45 as a transmission-blocking vaccine candidate against malaria |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614448/ https://www.ncbi.nlm.nih.gov/pubmed/31285498 http://dx.doi.org/10.1038/s41598-019-46375-6 |
work_keys_str_mv | AT mamedovtarlan aplantproducedinvivodeglycosylatedfulllengthpfs4845asatransmissionblockingvaccinecandidateagainstmalaria AT cicekkader aplantproducedinvivodeglycosylatedfulllengthpfs4845asatransmissionblockingvaccinecandidateagainstmalaria AT miurakazutoyo aplantproducedinvivodeglycosylatedfulllengthpfs4845asatransmissionblockingvaccinecandidateagainstmalaria AT gulecburcu aplantproducedinvivodeglycosylatedfulllengthpfs4845asatransmissionblockingvaccinecandidateagainstmalaria AT akinciersin aplantproducedinvivodeglycosylatedfulllengthpfs4845asatransmissionblockingvaccinecandidateagainstmalaria AT mammadovagunay aplantproducedinvivodeglycosylatedfulllengthpfs4845asatransmissionblockingvaccinecandidateagainstmalaria AT hasanovagulnara aplantproducedinvivodeglycosylatedfulllengthpfs4845asatransmissionblockingvaccinecandidateagainstmalaria AT mamedovtarlan plantproducedinvivodeglycosylatedfulllengthpfs4845asatransmissionblockingvaccinecandidateagainstmalaria AT cicekkader plantproducedinvivodeglycosylatedfulllengthpfs4845asatransmissionblockingvaccinecandidateagainstmalaria AT miurakazutoyo plantproducedinvivodeglycosylatedfulllengthpfs4845asatransmissionblockingvaccinecandidateagainstmalaria AT gulecburcu plantproducedinvivodeglycosylatedfulllengthpfs4845asatransmissionblockingvaccinecandidateagainstmalaria AT akinciersin plantproducedinvivodeglycosylatedfulllengthpfs4845asatransmissionblockingvaccinecandidateagainstmalaria AT mammadovagunay plantproducedinvivodeglycosylatedfulllengthpfs4845asatransmissionblockingvaccinecandidateagainstmalaria AT hasanovagulnara plantproducedinvivodeglycosylatedfulllengthpfs4845asatransmissionblockingvaccinecandidateagainstmalaria |